Table 3.
Univariate and multivariate analysis for event-free survival (EFS).
| Clinical variables | Event rate | EFS | ||
|---|---|---|---|---|
| HR | 95% CI | P | ||
| Univariate analysis | ||||
| Age (> 60) | 6/21 | 1.38 | 0.46–4.14 | 0.566 |
| Male gender | 7/27 | 1.02 | 0.34–3.06 | 0.968 |
| Ann Arbor Stage, III-IV | 9/14 | 7.62 | 2.33–24.92 | 0.001 |
| LDH elevation | 9/19 | 11.67 | 2.44–55.73 | 0.002 |
| B symptom | 6/12 | 2.96 | 0.99–8.85 | 0.053 |
| IPI score 3–5 | 6/11 | 3.89 | 1.28–11.76 | 0.016 |
| No surgical resection | 8/13 | 5.05 | 1.63–15.68 | 0.005 |
| Non-colon lesion SUVmax > 7.8 | 12/31 | 7.98 | 1.04–61.56 | 0.046 |
| Non-colon lesion MTV > 56.5 | 10/15 | 10.51 | 2.87–38.51 | 0.001 |
| Non-colon lesion TLG > 636.1 | 10/13 | 15.39 | 4.17–56.84 | 0.001 |
| Total lesion MTV > 80.0 | 12/25 | 18.79 | 2.39–147.9 | 0.005 |
| Total lesion TLG > 1,288.7 | 10/23 | 8.19 | 1.78–37.65 | 0.007 |
| Multivariate analysis | ||||
| Non-colon lesion TLG > 636.1 | 15.39 | 4.17–56.84 | 0.001 | |
HR = hazard ratio; CI = confidence interval; LDH, lactate dehydrogenase; IPI, International Prognostic Index; SUVmax, Maximum standard uptake value; MTV, Metabolic tumor volume; TLG, Total lesion glycolysis.